All In Biotech

Investigational drug · Phase 3

delpacibart braxlosiran

Also called: AOC-1020, del-brax

Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for FSHD, FSHD1, FSHD2.

Phase 3

Last checked: Nov 20, 2026Latest source record: Jul 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

3

2 still active

All registered trials

2

Any phase or sponsor naming "delpacibart braxlosiran"

First trial start

2023

Apr 4, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "delpacibart braxlosiran", any sponsor or status.

Conditions studied

As listed on its trial records.

  • FSHD
  • FSHD1
  • FSHD2
  • Fascioscapulohumeral Muscular Dystrophy
  • Fascioscapulohumeral Muscular Dystrophy Type 1
  • Fascioscapulohumeral Muscular Dystrophy Type 2
  • Facioscapulohumeral Muscular Dystrophy 1
  • Facio-Scapulo-Humeral Dystrophy
  • Facioscapulohumeral Muscular Dystrophy 2
  • FSH Muscular Dystrophy

Approved drugs for the same conditions: Rare and genetic disease

Largest trials

Live from ClinicalTrials.gov: studies naming "delpacibart braxlosiran" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 1 on PubMed

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.